1. |
systematic review for the American College of Physicians. American College of Physicians. Ann Intern Med, 2006, 144(8): 581-595.
|
2. |
Smetana GW, Lawrence VA, Cornell JE, et al. Preoperative pulmonary risk stratification for noncardiothoracic surgery:.
|
3. |
Kutlu C, Williams E, Evans E, et al. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg, 2000, 69: 376-380.
|
4. |
Gibbs BF, Schmutzler W, Vollrath IB, et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res, 1999, 48(2): 86-93.
|
5. |
Stetinová V, Herout V, Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin Exp Med, 2004, 4(3): 152-158.
|
6. |
周海洋, 常業恬, 呂志平, 等. 鹽酸氨溴索對瓣膜置換患者圍術期肺損傷的保護作用. 中南大學學報醫學版, 2004, 29(6): 723-724.
|
7. |
方曉惠, 鈕善福. 沐舒坦針劑治療呼吸系統疾病療效觀察. 上海醫科大學學報, 2000, 27(2): 152-153.
|
8. |
Fegiz G. Prevent ion by Ambroxol of Bronchopulmonary Complications after Upper Abdominal Surgery: Double-Blind Italian Multicenter Clinical Study versus Placebo. Lung, 1991, 169: 69-76.
|
9. |
Tan LJ, Liu YQ, Xu ST, et al. Role of ambroxol in protection of the decrease of PS in lung injury after thoracotomy. Journal of Shanghai Medical University, 2000, 27(6): 484-487.
|
10. |
劉君, 崔飛, 何建行, 等. 大劑量沐舒坦在微創胸外科術后的臨床應用效果. 實用醫學雜志, 2006, 22(16): 1930-1931.
|
11. |
夏宏偉, 祝滬軍, 方秦模, 等. 沐舒坦在預防食管癌術后呼吸系統并發癥的應用. 齊齊哈爾醫學院學報, 2008, 29(5): 558-599.
|
12. |
崔玉, 張偉峰. 食管癌患者術后應用沐舒坦的療效觀察. 醫藥產業資訊, 2005, 2(5): 58-60.
|
13. |
羅文杰, 薛慶生. 沐舒坦對老年患者術后呼吸系統并發癥的預防作用. 臨床麻醉學雜志, 2005, 21(9): 603-604.
|
14. |
郝孟輝, 陳志全, 王東軍, 等. 沐舒坦預防胸部手術并發癥的臨床療效及安全性研究. 中國綜合臨床, 2003, 19(9): 847-848.
|
15. |
陳蘭平, 張亞軍, 施東輝, 等.鹽酸氨溴索對體外循環心臟直視手術肺保護作用的臨床研究. 中國心血管病研究雜志, 2005, 3(3):.
|
16. |
Derelle J, Bertolo-Houriez E, Marchal F, et al. Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa. Arch Pediatr, 1998, 5(4): 371-377.
|
17. |
Wirtz HR. Effect of ambroxol on surfactant secretion and synthesis in isolated type II alveolar cells. Pneumologie, 2000, 54(7): 278-283.
|
18. |
Frerking I, Günther A, Seeger W, et al. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med, 2001, 27(11): 1699-1717.
|
19. |
Kinugasa S, Tachibana M, Yoshimura H, et al. Postoperative pulmonary complications are associated with worse short- and longterm outcomes after extended esophagectomy. J Surg Oncol, 2004, 88(2): 71-77.
|
20. |
Algar FJ, Alvarez A, Salvatierra A, et al. Predicting pulmonary complications after pneumonectomy for lung cancer. European Journal of Cardio-thoracic Surgery, 2003, 23: 201-208.
|
21. |
McAlister FA, Bertsch K, Man J, et al. Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med, 2005, 171: 514-517.
|
22. |
Hwang D, Shakir N, Limann B, et al. Association of sleep-disordered breathing with postoperative complications. Chest, 2008, 133(5): 1128-1134.
|
23. |
Smetana GW. Preoperative Pulmonary Evaluation. N Engl J Med.,1999, 340: 937-944.
|
24. |
Laoag-Fernandez JB, Fernandez AM, Maruo T. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. J Obstet Gynaecol Res, 2000, 26(4): 307-312.
|
25. |
董玉清, 沈鵬, 李洋, 等. 大劑量鹽酸氨溴索在普胸外科圍手術期的臨床效果觀察. 中外健康文摘, 2007, 4(2): 106.
|
26. |
鄭艷輝, 曠壽金. 不同劑量氨溴索對哮喘豚鼠肺表面活性物質的影響. 中國醫師雜志, 2003, 增刊: 5-6.
|
27. |
-191.
|